182 related articles for article (PubMed ID: 34617686)
1. Suppression of collagen IV alpha-2 subunit by prolyl hydroxylase domain inhibition via hypoxia-inducible factor-1 in chronic kidney disease.
Sanaei-Ardekani M; Kamal S; Handy W; Alam S; Salaheldin A; Moore A; Movafagh S
Pharmacol Res Perspect; 2021 Oct; 9(5):e00872. PubMed ID: 34617686
[TBL] [Abstract][Full Text] [Related]
2. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.
Kato S; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2020 Feb; 372(2):166-174. PubMed ID: 31801803
[TBL] [Abstract][Full Text] [Related]
3. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
[TBL] [Abstract][Full Text] [Related]
4. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
Uchida L; Tanaka T; Saito H; Sugahara M; Wakashima T; Fukui K; Nangaku M
Am J Physiol Renal Physiol; 2020 Feb; 318(2):F388-F401. PubMed ID: 31841388
[TBL] [Abstract][Full Text] [Related]
5. Effects of prolyl-hydroxylase inhibition and chronic intermittent hypoxia on synaptic transmission and plasticity in the rat CA1 and dentate gyrus.
Wall AM; Corcoran AE; O'Halloran KD; O'Connor JJ
Neurobiol Dis; 2014 Feb; 62():8-17. PubMed ID: 24055213
[TBL] [Abstract][Full Text] [Related]
6. Prolyl-hydroxylase inhibition induces SDF-1 associated with increased CXCR4+/CD11b+ subpopulations and cardiac repair.
Ghadge SK; Messner M; Van Pham T; Doppelhammer M; Petry A; Görlach A; Husse B; Franz WM; Zaruba MM
J Mol Med (Berl); 2017 Aug; 95(8):825-837. PubMed ID: 28550361
[TBL] [Abstract][Full Text] [Related]
7. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
8. The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation.
Palaniyandi S; Kumari R; Venniyil Radhakrishnan S; Strattan E; Hakim N; Munker R; Kesler MV; Hildebrandt GC
Transplantation; 2020 Dec; 104(12):2507-2515. PubMed ID: 32639407
[TBL] [Abstract][Full Text] [Related]
9. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia inducible factor-1 alpha promotes mesangial cell proliferation in lupus nephritis.
Deng W; Ren Y; Feng X; Yao G; Chen W; Sun Y; Wang H; Gao X; Sun L
Am J Nephrol; 2014; 40(6):507-15. PubMed ID: 25531641
[TBL] [Abstract][Full Text] [Related]
11. Activation of Hif1α by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity.
Ayrapetov MK; Xu C; Sun Y; Zhu K; Parmar K; D'Andrea AD; Price BD
PLoS One; 2011; 6(10):e26064. PubMed ID: 22016813
[TBL] [Abstract][Full Text] [Related]
12. Acute hypoxic exposure and prolyl-hydroxylase inhibition improves synaptic transmission recovery time from a subsequent hypoxic insult in rat hippocampus.
Lanigan S; Corcoran AE; Wall A; Mukandala G; O'Connor JJ
Brain Res; 2018 Dec; 1701():212-218. PubMed ID: 30244114
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
He J; Jia Z; Zhang A; Bai M
Pediatr Nephrol; 2024 Jan; 39(1):37-48. PubMed ID: 37284874
[TBL] [Abstract][Full Text] [Related]
14. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Sugahara M; Tanaka T; Nangaku M
Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
16. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of prolyl hydroxylase domain-containing protein suppressed lipopolysaccharide-induced TNF-alpha expression.
Takeda K; Ichiki T; Narabayashi E; Inanaga K; Miyazaki R; Hashimoto T; Matsuura H; Ikeda J; Miyata T; Sunagawa K
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2132-7. PubMed ID: 19762779
[TBL] [Abstract][Full Text] [Related]
18. Systemic hypoxia mimicry enhances axonal regeneration and functional recovery following peripheral nerve injury.
Smaila BD; Holland SD; Babaeijandaghi F; Henderson HG; Rossi FMV; Ramer MS
Exp Neurol; 2020 Dec; 334():113436. PubMed ID: 32814068
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
Sakashita M; Tanaka T; Nangaku M
Contrib Nephrol; 2019; 198():112-123. PubMed ID: 30991411
[TBL] [Abstract][Full Text] [Related]
20. Sestrin2 inhibits hypoxia-inducible factor-1α accumulation via AMPK-mediated prolyl hydroxylase regulation.
Seo K; Seo S; Ki SH; Shin SM
Free Radic Biol Med; 2016 Dec; 101():511-523. PubMed ID: 27840318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
